Antineoplastic Agents: Cytotoxic Agents: Antimetabolites
OHYDR1 “Hydrea capsule” 500 mg/cap
適應症：黑色素瘤、抵抗性慢性髓性白血病、復發、轉移或不可開刀之卵巢癌；與輻射線治療併用於陰唇外之原發性頭及頸麟狀細胞癌之局部控制。
Usual dose:
Chronic myelogenous leukemia: 20-30 mg/kg PO qd.
Head and neck cancer: 80 mg/kg PO single dose q3d; 20-30 mg/kg/day PO continuous therapy.
Melanoma: 80 mg/kg PO single dose q3d; 20-30 mg/kg/day PO continuous therapy.
Ovarian cancer: 80 mg/kg PO single dose q3d; 20-30 mg/kg/day PO continuous therapy.
Sickle cell disease: 15-35 mg/kg PO qd.
Adverse effect:
Common: myelosuppression.
Serious: mutagenicity/secondary leukemias (long-term use).
Related Entries
(Visited 35 times, 1 visits today)